A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate Asthma
Primary Purpose
Asthma
Status
Completed
Phase
Phase 2
Locations
United Kingdom
Study Type
Interventional
Intervention
FTY720
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Asthma focused on measuring Asthma, adrenergic beta agonists, multiple sclerosis, pulmonary function tests, forced expiratory volume
Eligibility Criteria
Inclusion Criteria:
- Forced Expiratory Volume in 1 second of at least 60%
- History of asthma for at least 6 months
- Current use of short-acting beta agonists, inhaled long-acting beta agonists and inhaled corticosteroids (up to a specified dose)
Exclusion Criteria:
- History of lung disease other than asthma
- Smokers
- Use of inhaled corticosteroid above specified dose
- Use of oral beta agonists or corticosteroids or other asthma medications
- Hypersensitivity to the drug
- Respiratory tract infections within 1 month of the study
Other protocol-defined inclusion/exclusion criteria may apply
Sites / Locations
- Novartis Investigator Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
1
2
Arm Description
Outcomes
Primary Outcome Measures
Change from baseline in Pulmonary function tests (particularly Forced Expiratory Volume at 1 sec (FEV1) at Day 10
Safety of FTY720
Secondary Outcome Measures
Use of short acting beta agonists during treatment compared to pre-treatment
Pharmacokinetics of FTY720 and FTY720-P
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00785083
Brief Title
A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate Asthma
Official Title
A Double-blind, Randomized, Placebo-controlled, Parallel, Time-lagged, Ascending, Multi-centre, Multiple-dose Study to Measure the Magnitude and Time Course of the Effect of FTY720 on FEV1 and Other Pulmonary Function Tests (FVC, FEF25-75%, and FEV1/FVC) in Patients With Moderate Asthma
Study Type
Interventional
2. Study Status
Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
September 2008 (undefined)
Primary Completion Date
February 2009 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study will evaluate the effect of FTY720 on the lung function of patients with moderate asthma
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Asthma, adrenergic beta agonists, multiple sclerosis, pulmonary function tests, forced expiratory volume
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
36 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Title
2
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
FTY720
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Change from baseline in Pulmonary function tests (particularly Forced Expiratory Volume at 1 sec (FEV1) at Day 10
Time Frame
10 days
Title
Safety of FTY720
Time Frame
10 days
Secondary Outcome Measure Information:
Title
Use of short acting beta agonists during treatment compared to pre-treatment
Time Frame
10 days
Title
Pharmacokinetics of FTY720 and FTY720-P
Time Frame
10 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Forced Expiratory Volume in 1 second of at least 60%
History of asthma for at least 6 months
Current use of short-acting beta agonists, inhaled long-acting beta agonists and inhaled corticosteroids (up to a specified dose)
Exclusion Criteria:
History of lung disease other than asthma
Smokers
Use of inhaled corticosteroid above specified dose
Use of oral beta agonists or corticosteroids or other asthma medications
Hypersensitivity to the drug
Respiratory tract infections within 1 month of the study
Other protocol-defined inclusion/exclusion criteria may apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis
Organizational Affiliation
Novartis Investigator Site
Official's Role
Principal Investigator
Facility Information:
Facility Name
Novartis Investigator Site
City
Manchester
Country
United Kingdom
12. IPD Sharing Statement
Citations:
PubMed Identifier
27121555
Citation
Boulton C, David OJ, Meiser K, Schmouder R. Tolerability and Pulmonary Pharmacodynamic Effects During Treatment Initiation of Once-Daily Oral Fingolimod in Subjects With Moderate Asthma. Clin Pharmacol Drug Dev. 2013 Jan;2(1):2-10. doi: 10.1002/cpdd.4. Epub 2013 Mar 4.
Results Reference
result
PubMed Identifier
24293455
Citation
Izquierdo G, O'Connor P, Montalban X, von Rosenstiel P, Cremer M, de Vera A, Sfikas N, Francis G, Radue EW, Kappos L. Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Mult Scler. 2014 Jun;20(7):877-81. doi: 10.1177/1352458513513059. Epub 2013 Nov 30.
Results Reference
derived
Learn more about this trial
A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate Asthma
We'll reach out to this number within 24 hrs